SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

20 Strong Positioning Among HCP Source: Zohydro ® ER ATU Jun 2018. (1) Questions asked of participants: What are your perceptions about the performance of Zohydro ® ER (hydrocodone bitartrate) extended release tablets on each of the following attributes? What are your perceptions about the performance of Hysingla ® ER (hydrocodone) extended release tablets on each of the following attributes? What are your perceptions about the performance of Xtampza ® ER (oxycodone) extended release tablets on each of the following attributes? 1 2 3 4 5 6 7 85% Well tolerated 82% Low patient out of pocket cost 82% Broad insurance coverage 65% No end - of - dose failure 64% Contains ADT 62% Few PA or step edits 61% Patient preference 51% Low prob of dose increase 50% Widely stocked in pharmacy 45% Dosing supportive of MME 45% Wide range of doses 38% Extensive clinical experience 32% Dual MOA 31% Ease of IR to ER Poor Excellent Mean Score (n=104) Importance (% Ranking in Top 10) Zohydro ® ER Hysingla ® ER Xtampza ® ER Perceptions of Performance of ER Tablets • Zohydro ® ER with BeakTek ® positioned strongly in the marketplace • Patients preferred Zohydro ® ER with BeakTek ® vs. other competitors’ products Zohydro ® ER 5.3 3.7 4.0 5.0 5.1 3.5 5.2 4.4 4.0 5.0 5.0 5.4 2.9 5.8